Check for updates

OPEN ACCESS

EDITED BY Adelaide Fernandes, University of Lisbon, Portugal

REVIEWED BY Nicolas Santander, Universidad de O'Higgins, Chile Kui Cui, Harvard University, United States

*CORRESPONDENCE Laijing Du, ⊠ 17395953051@163.com

RECEIVED 16 August 2024 ACCEPTED 08 October 2024 PUBLISHED 25 October 2024

CITATION

Guo J and Du L (2024) An update on ox-LDLinducing vascular smooth muscle cell-derived foam cells in atherosclerosis. *Front. Cell Dev. Biol.* 12:1481505. doi: 10.3389/fcell.2024.1481505

COPYRIGHT

© 2024 Guo and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

An update on ox-LDL-inducing vascular smooth muscle cell-derived foam cells in atherosclerosis

Jingjing Guo¹ and Laijing Du²*

¹Luoyang Key Laboratory of Cardiovascular Science, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China, ²Department of Cardiology, Henan Key Laboratory of Cardiovascular Science, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China

Excess cholesterol accumulation induces the accumulation of foam cells, eventually accelerating atherosclerosis progress. Historically, the mechanisms of macrophage-derived foam cells have attracted attention because of their central role in plaque development, which was challenged by lineage tracing in union with single-cell sequencing (sc-seq). Accumulated studies have uncovered how vascular smooth muscle cells (VSMCs) proliferate and migrate to the vascular intima and accumulate, then transform into foam cells induced by surplus lipids, finally accounting for 30% to 70% of the total foam cells within the plaque of both mice and humans. Therefore, the mechanisms of VSMC-derived foam cells have received increasing attention. The review intends to summarize the transformation mechanism of VSMCs into foam cells induced by oxidized low-density lipoproteins (ox-LDL) in atherosclerosis.


KEYWORDS

VSMCs, foam cell, atherosclerosis, ox-LDL, cholesterol metabolism

Introduction

Atherosclerosis is a widespread and critical public health issue that is one of the leading causes of death globally (Barquera et al., 2015). In the presence of oxidized low-density lipoproteins (ox-LDLs), subendothelial vascular smooth muscle cells (VSMCs) in the human aorta increase the expression of macrophage marker cluster of differentiation 68 (CD68) and decrease SMC marker α -smooth muscle actin (α -SMA) expression (Andreeva et al., 1997). With the help of multicolor-labeling and random recombinant fluorescent transgene mice technology, accumulated studies found that the plaque comprised macrophage-like cells (CD68, galectin-3 (LGALS3/MAC2), and lysosomal associated membrane protein 2 (LAMP2/MAC3)), which came from a small subpopulation of VSMCs (Chappell et al., 2016; Jacobsen et al., 2017; Misra et al., 2018). Recently, studies found that a minimum of 50% to 70% of foam cells were individually redifferentiated from VSMCs in human coronary artery and apolipoprotein E-deficient mice plaques (Wang Y. et al., 2019; Allahverdian et al., 2014). Therefore, the importance of foam cells that are derived from VSMCs, especially in the progression of lesions, has been prominently highlighted (Pan et al., 2023).

VSMCs are an integral part of the vascular media and exhibit high phenotypic plasticity (Alencar et al., 2020; Grootaert and Bennett, 2021). Much ox-LDL migrates into the subendothelial space. Then, ox-LDL is transferred into VSMCs through lectin-like oxidized



acquire a macrophage-like phenotype to become foam cells.

low-density lipoprotein 1 (LOX-1), type A scavenger receptor (SR-A), platelet glycoprotein 4 (CD36), CXCL16/SR-PSOX, and other scavenger receptors, and redifferentiates into foam cells. During this process, VSMCs decrease the expression of VSMC markers (myosin heavy chain 11 (MYH11), α -SMA, and calponin 1) and increase the expression of macrophage markers (CD68, galectin, and Mac-2) (Wang Y. et al., 2019; Allahverdian et al., 2014; Rong et al., 2003; Wågsäter et al., 2004) (Figure 1). However, the process of how VSMCs transform into foam cells remains unclear. Therefore, the mechanism of VSMC-derived foam cell formation is discussed in this review, with an emphasis on recent developments.

Origin of VSMC-derived foam cells

VSMCs are the core members of the medial arteries. Previously, due to the failure to trace VSMCs during the phenotypic switch, the

important role of VSMC-derived foam cells was ignored (Bennett et al., 2016). Utilizing tamoxifen-inducible CreERT2 recombinase driven by VSMC-specific promoters (Tagln or Myh11), studies have revealed that VSMC-derived foam cells in advanced lesions upregulate the expression of macrophage markers and downregulate the expression of VSMC markers (Feil et al., 2014). Immunostaining for detecting VSMCs based on VSMC markers leads to ignoring more than 80% of VSMC-derived cells in plaque in a mouse model (Shankman et al., 2015). Dubland and Francis found approximately 50% of foam cells came from the redifferentiation of human VSMCs (Shankman et al., 2015). Ashish Misra et al. proposed that pre-existing SMCs divide into (SMA)+ cells and predominantly (SMA)⁻ cells and that most plaque cells originate from the proliferation of a single (SMA)⁺ cell. However, in the aortic media, the progenitor cells or cell pools marked with VSMC markers that participated in the formation of early atherosclerotic plaques have not yet been identified (Misra et al., 2018).

With the help of sc-seq technologies, the phenotypic heterogeneity of foam cells derived from VSMCs has been revealed (Pan et al., 2020). For example, SEM (VSMC-derived intermediate cells), which are intermediate cells derived from VSMCs, differentiating exhibit multipotency, into fibrochondrocyte-like and macrophage-like cells, while likewise reverting to the VSMC phenotype (Pan et al., 2020). Recently, Austin et al. analyzed VSMC transcriptomic single-cell data, especially those originating from models of atherosclerotic mice. The result indicated that Mac-2 is a transitioning phenotype during reprogramming from VSMCs to macrophage-like cells. However, intermediate states and the path of the phenotype switch of VSMCs, re-differentiating into macrophage-like cells, are still inadequate (Conklin et al., 2021).

It is still unclear whether VSMCs must first exhibit characteristics of macrophages during the process of transforming into foam cells or whether they begin to display these characteristics only after the transformation. Huize Pan and colleagues also reported that macrophage-like cells originating from VSMCs emerged later in lesions than resident or myeloid-derived macrophages. This finding, based on single-cell genomic analysis and SMC lineage tracing, may be questioned because of the diversity of the mice model as well as variances in the preparation techniques of single cells (Pan et al., 2020).

The detailed landscape of the VSMC-derived foam cells induced by ox-LDL in plaque needs further study.

Consequences of VSMC-derived foam cell

The fate of foam cells, including apoptosis, autophagy, necrosis, and pyroptosis, plays an important role in regulating the formation and stability of atherosclerotic lesions. VSMC-derived foam cells mainly comprise the neointima of plaque (Bashore et al., 2024), and the death of VSMC-derived foam cells plays an important role in plaque stability. Apoptosis of VSMCs promotes the formation and expansion of necrotic cores and macrophage infiltration. Ox-LDL promoted apoptosis of VSMCs through activation of caspase cascade reaction, including Forkhead Transcription Factor O Subfamily Member 3(FOXO3)/ Apoptotic Protease Activating Factor 1(APAF1) and tensin homolog deleted on chromosome ten/ Phosphoinositide 3 kinase (PI3K)/Protein Kinase B(AKT), which led to plaques that are more prone to rupture (Yu et al., 2018; Huang and Kontos, 2002). In AS, efferocytosis, being eaten by the surrounding macrophages, is impaired in foam cells. Apoptosis of VSMCs is cleared by efferocytosis. The studies emphasized the clearance of apoptotic cells is crucial for the treatment of atherosclerosis (Yurdagul et al., 2020). Zheng Yin et al. suggested that EDIL3/Del-1 participated in the efferocytosis of apoptotic VSMCs in aortic dissection (Yin et al., 2024). Knockout of cyclindependent kinase inhibitor 2B impaired efferocytosis (Kojima et al., 2019). Recent studies found that VSMCs induced by thrombin acquired the ability to escape efferocytosis through upregulation of CD47 (Moldogazieva et al., 2019; Sun et al., 2022). Inefficient clearance of apoptotic VSMCs accelerated the formation of necrosis (Clarke et al., 2006). If apoptotic VSMCs fail to clear, necrosis, a non-programmed death form, will occur in VSMCs from atherosclerotic plaques (Bennett et al., 2016). However, ox-LDL alone fails to induce necroptosis of VSMCs (Dubland and Francis, 2016). Therefore, the strategy to

enhance the clearance of VSMC-derived foam cells is important for the treatment of AS.


The deficiency of autophagy of VSMC-derived foam cells will be debated below. Adequate autophagy is crucial in the treatment of AS. Lipophagy, the targeted breakdown of lipid droplets, is a selective form of autophagy (Robichaud et al., 2021). It aims to degrade LDs and inhibits the formation of VSMC-derived lysosomes (Bai et al., 2022; Jeong et al., 2021; Yoo et al., 2021). Accumulated studies suggested that stearoyl-CoA desaturase-1 (SCD1) promoted the activation and nucleus translocation of transcription factor EB (TFEB), preventing the accumulation of LDs in VSMC-derived foam cells. This could potentially present a new direction for therapeutic interventions targeting atherosclerosis (Pi et al., 2019). IPARP1 was found to disrupt the molecular interaction between ATP-binding cassette G1 (ABCG1) and PLIN1, a critical association in cellular lipid metabolism, and enhanced that of P62 within LDs, which led to the accumulation of LDs (Lin et al., 2024). In addition, Ox-LDL induces the pyroptosis and ferroptosis of VSMCs, which promotes the formation of foam cells and plaque rupture (Wang et al., 2020; He et al., 2023; Zhou et al., 2021). However, the fates of VSMC-derived cells remain uncharacterized during plaque regression. The main reason is that it is difficult to trace the precise dynamic process and mimic a 3D environment in vitro.

Regulation of cholesterol metabolism in VSMC-derived foam cells

Most cholesterol within lipoproteins exists as cholesteryl fattyacyl esters (CEs). The equilibrium between CEs and free cholesterol (FC) is crucial for managing cholesterol levels in VSMCs (Liu et al., 2021). Ox-LDLs are uptaken via scavenger receptors and are hydrolyzed to FC by lysosomal acid lipase (LAL) in the lysosome (Kzhyshkowska et al., 2012; Park, 2014; Moore and Freeman, 2006). Excess FC is often repackaged into CEs by ACAT1 in the endoplasmic reticulum (ER) and then stored in cytoplasmic lipid droplets or effluxed through ATP-binding cassette (ABC) transporters (Mulas et al., 2014; Yin et al., 2014; Dubland and Francis, 2015; Chen L. et al., 2022) (Figure 2). In AS, the surplus of CEs leads to much FC retention in lysosomes. Once the processing capacity of lysosomes is surpassed, excess FC crystallizes. Cholesterol crystals cause overactive scavenger receptors (SR), and endocytosis forms numerous cytoplasmic lipid droplets and further promotes the formation of foam cells. In addition, cholesterol crystals in VSMC foam cells trigger apoptosis and expel cellular debris into the extracellular environment (Ho-Tin-Noé et al., 2017). Understanding cholesterol metabolism, therefore, is vital for AS treatment. This review mainly summarizes the role of ox-LDL in VSMC-derived foam cell formation from three aspects: the uptake of ox-LDL, the cyclic metabolism of cholesterol, and defective VSMC-derived foam cells, and also addresses the related regulatory mechanisms.

Scavenger receptors

VSMCs take up modified LDLs, such as ox-LDL and aggregation-LDL (ag-LDL), via class B scavenger receptors (SR-B1 and SR-B2, or CD36) (Ben et al., 2015), SR-A (Shen et al., 2018),



hydrolyzed to free cholesterol (FC) at an acidic pH by lysosomal acid lipase (LAL), encoded by the LIPA (lipase A) gene in the lysosome. Once there is an FC surplus, they are shifted to the endoplasmic reticulum (ER). FC re-esterifies to CEs by acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT1) and accumulates in the ER. Under normal conditions, CEs were stored in lipid droplets. If they accumulate in excess, VSMCs become foam cells. NCEH breaks down CEs and releases FC. FC is transported outside the cell via the ATP-binding cassette transporters (ABC) ABCA1 and ABCG1. ApoA-1 acts as a cholesterol transport receptor for ABCA1. Meanwhile, HDL serves as a recipient, collecting cholesterol transferred by ABCG1 and SR-BI. Lysosomally derived FC also provides the substrate for conversion to the oxysterol 27-hydroxycholesterol (27-OHC) in mitochondria by sterol-27-hydroxylase (CYP27A1). 27-OHC then travels to the nucleus, where it binds to liver X receptors (LXRs) on the promoter region of ABCA1 and other cholesterol export genes, including ABCG1, to upregulate their expression and facilitate efflux of the excess FC from cells.

lectin-like oxidized low-density lipoprotein 1 (LOX-1 or SR-E1) (Sawamura et al., 1997) and the SR for phosphatidylserine and oxidized lipoprotein (SR-PSOX/CXCL16) (Moore and Freeman, 2006). Shu H et al. demonstrated that 75%–90% of modified lipoproteins are uptaken through CD36 and SR-A (Shu et al., 2022). In contrast, Manning-Tobin and colleagues uncovered that knockout of CD36 and SR-A among $ApoE^{-/-}$ mice did not affect lesion size and macrophage/foam cell content (Deaton et al., 2009; Manning-Tobin et al., 2009).

SR-A

SR-A, belonging to the SR family, is expressed in VSMCs (Kodama et al., 1990; Daugherty et al., 1997; Li et al., 1995). It mainly interacts with ox-LDL and ac-LDL and changes with lipid internalization (Moore and Freeman, 2006). Suzuki et al. reported that knockout of SR-A1 in ApoE^{-/-} mice reduced cholesterol uptake and protected against atherosclerotic development (Suzuki et al., 1997). When cells are exposed to transforming growth factor- β 1 (TGF- β 1) and ox-LDL *in vitro*, SR-AII and SR-AI levels are elevated in VSMCs (Li et al., 1995; Gong and Pitas, 1995; Yan et al., 2011). Krüppel-like factor 4 (KLF4) suppresses SR-A transcriptionally, and

formononetin substantially attenuates the interplay between KLF4 and SR-A in VSMCs (Ma et al., 2020).

Scavenger receptor class B type I (SR-BI)

It is known that SR-BI is the core receptor for high-density lipoprotein (HDL) and mainly participates in cholesterol efflux (Phillips, 2014). Note that SR-BI also participates in the regulation of cholesterol influx. In endothelial cells (ECs), SR-BI is not only shown to inhibit the progress of AS by inducing the formation of nitric oxide but also promotes AS through enhancing LDL transcytosis (Mineo and Shaul, 2003; Yuhanna et al., 2001). However, whether SR-BI exhibits an atheroprotective effect in vascular tissue is unclear. Recent studies found SR-BI was a protective compensatory mechanism that maintained cholesterol homeostasis without ABCG1 (Oladosu et al., 2023).

CD36

CD36 was originally identified in the late 1980s and is in the SR family class B (Rao et al., 2014; Yu et al., 2013; Oquendo et al., 1989). Lesion development is significantly reduced in CD36^{-/-}/ApoE^{-/-} mice (Febbraio et al., 2000). CD36 expression increases after

treatment with ox-LDL, high glucose, or oleic acid, which enhances lipid accumulation in human coronary VSMCs. (Ma et al., 2011; Schlich et al., 2015; Xue et al., 2010). Accumulated studies found triggering receptor expressed in myeloid cells 2 (TREM2) expressions were raised in plaques (Depuydt et al., 2020; Cochain et al., 2018; Willemsen and de Winther, 2020; Guo et al., 2023). Ox-LDL activated PI3K/AKT, p38 mitogen-activated protein kinases (MAPK), and c-Jun N-terminal kinase (JNK) signaling pathways and enhanced the expression of HDGF and TREM2, which upregulated the expression of LOX-1 and CD36 (Guo et al., 2023). Meanwhile, ox-LDL induced Wnt Family member 5A (WNT5A) autocrine signaling and then activated disheveled segment polarity protein 2 (DVL2)/JNK signaling, which raised the level of CD36 (Ackers et al., 2020). Urszula Rykaczewska et al. found that Bcl2-associated transcription factor 1-ribosomal protein S8-tetraspanin-9-CD36 participated in the regulation and fate of VSMCs transforming into foam cells (Rykaczewska et al., 2022).

LOX-1

LOX-1, which accelerates foam cell production, is expressed in VSMCs (Sawamura et al., 1997) and accounted for 5%-10% of ox-LDL uptake (Mehta et al., 2007; Schaeffer et al., 2009). Ox-LDL induces VSMC transformation to foam cells through mtROS/c-Fos/ LOX-1, which promotes ox-LDL uptake (Miao et al., 2022). In contrast, Zhang W et al. found ox-LDL suppressed the activity of non-receptor tyrosine kinase on the alpha1 C subunit (CACNA1C) and the L-Ca channel subunit, which led to downregulation of LOX-1 and subsequently promoted the proliferation, migration, and foam cell formation. Importantly, genistein mitigated these effects (Zhang et al., 2022). Zheng et al. also suggested that ox-LDL promoted autophagic degradation of LOX-1 (Zheng Y. et al., 2023). Deng et al. found that LKB1 participated in the regulation of the expression of LOX-1, which activated sirtuin 6 (SIRT6) through direct phosphorylation and then histone deacetylation of the promoter of LOX-1 (Deng et al., 2023). Myotoxin III, which is consistent in structure and function with phospholipase A2, upregulated the expression of SR-A and LOX-1 through PPAR-γ and PPAR-β/δ and enhanced intake of acetylated low-density lipoprotein (ac-LDL) in VSMCs (Giannotti et al., 2019). Poria coco polysaccharides inhibited the expression of LOX-1 induced by ox-LDL (Zhao et al., 2020). However, LOX-1 activation promoted oxidative stress, yielding higher ox-LDL production, thereby enhancing cycle self-amplification (Xu et al., 2013).

SR-PSOX/CXCL16

SR-PSOX/CXCL16, a class G member of the SR family, is expressed in VSMCs in human AS plaques and primarily binds and internalizes the ox-LDL (Zanoni et al., 2018) (Wågsäter et al., 2004; PrabhuDas et al., 2017; Minami et al., 2001; Hofnagel et al., 2002). IFN- γ notably stimulates CXCL16 expression in human VSMCs and increases ox-LDL uptake. However, this process does not influence CD36 and LOX-1 levels (Wågsäter et al., 2004).

Low-density lipoprotein receptor (LRP1)

Belonging to the LDLR family, LRP1 is expressed in VSMCs and is responsible for LDL uptake (Boucher et al., 2003; Llorente-Cortés et al., 2000). In VSMCs, knockout of LRP1 makes individuals more prone to cholesterol-induced atherosclerosis via the signaling pathways of platelet-derived growth factor receptor (PDGFR) and TGF- β (Boucher et al., 2003; Boucher et al., 2007). LRP1 has a protective function against atherosclerosis through modulating ATP-binding cassette A1 (ABCA1) expression via extracellular regulated protein kinases 1/2 (ERK1/2)/cytosolic phospholipase A2 (cPLA2/)arachidonic acid (Graves et al., 1996; Lin et al., 1992), an inhibitor of ABCA1 expression driven by liver X receptors (LXR) (DeBose-Boyd et al., 2001). Gordts PL et al. suggested LRP1 NPxYxxL motif is essential in LRP1's antiatherosclerotic function (Gordts et al., 2009). Therefore, atherosclerosis development can be mitigated via LRP1. In contrast, higher levels of LRP1 and intracellular lipid deposition were found in VSMCs that originated in advanced human plaques (Llorente-Cortés and Badimon, 2005). In vivo, ag-LDL induces expression of LRP1 in VSMCs and, in turn, promotes ag-LDL internalization through cluster II CR9 domain's C-terminal half (Llorente-Cortés et al., 2002; Costales et al., 2015). Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates the metabolism of LDL through LDLR and facilitates foam cell formation via SNHG16/EZH2/H3K27me3/TRAF5 in VSMCs (Liu et al., 2023; Glerup et al., 2017). Thus, LRP1 may exert opposing effects in VSMCs. The dual function of LRP1 in the metabolism of LDL in VSMCs remains unclear.

Hydrolysis of CEs to FC in the lysosomes

Lysosomal acid lipase (LAL), encoded by lipase A gene (LIPA), is the sole enzyme for hydrolyzing CEs to FC in late endosomes/ lysosomes, which is called lipophagy, or selective autophagy (Ouimet et al., 2011). In both human and mouse atherosclerosis, LAL prevents the overload of intracellular lipids and sustains cholesterol balance, which is the core progress to regulate VSMC-derived foam cell formation (Dubland and Francis, 2015; Dubland et al., 2021). However, Dubland and Jerome found impaired lysosomal function or deficiency of LIPA/LAL is an inherent characteristic that is not related to species in SMCs rather than a gene deficiency that is specific to a subset of individuals. Dubland et al. also suggested that the upregulation of LIPA or increasing activity of VSMC is an effective strategy for enhancing the processing of intracellular accumulated cholesterol in VSMC-derived foam cells. FOXO1 or TFEB is the activator of LIPA expression and the function of LAL. However, further studies are required to understand how upregulating these activators inhibits VSMC-derived foam cell formation.

Re-esterification of FC to CEs in the ER

ACAT1 catalyzes FC to CEs in the ER and is stored in cytosolic LDs (Suckling and Stange, 1985; Rudel et al., 2001). Accumulative evidence supports that many CEs accumulate in VSMCs or macrophage-derived foam cells and accelerate plaque formation (Ross, 1993). Higashimori et al. identified toll-like receptor 4 (TLR4) deficiency inhibited ACAT1 expression and formation of VSMC-derived foam cells induced by free cholesterol (Higashimori et al., 2011). Y-W Yin et al. further found that PPAR γ inhibited the expression of ACAT1 through TLR4/MyD88/NF- κ B (Yin et al., 2014). Bethany J Bogan et al. reported fatty acid synthase (FASN), which synthesized fatty acids, was upregulated in atherosclerotic human coronary arteries and induced foam cells derived from SMCs when exposed to cholesterol, which not only induced

CD68 expression through KLF4/sterol O-acyltransferase 1 (SOAT1) but also inhibited ABCA1 expression to limit cholesterol efflux. FASN, therefore, acts in the biosynthesizing of fatty acids and functions in cholesterol esterification's inverse association with efflux (Bogan et al., 2024).

Blocking LD formation by knocking down liquid droplet-associated proteins (LDAPs)

Liquid droplet-associated proteins (LDAPs), which are situated on the exterior of lipid droplets (LDs), are crucial for their assembly and breakdown processes (Yuan et al., 2012). PLIN2, belonging to the PAT family, is considered a scaffold protein for LD formation and is expressed in foam cells (Paul et al., 2008; Becker et al., 2010). During the process of lipid accumulation, PLIN2 relocates from the cell's periphery to the cytoplasmic region, where it aids in the sequestration of long-chain fatty acids and the genesis of lipid droplets. (Gao et al., 2000). Myotoxin III (MT-III) facilitates the translocation of PLIN2 and PLIN3 from their usual repositories, underscoring the significance of these proteins in the assembly of lipid droplets within VSMCs (Giannotti et al., 2019). MT-III, an Asp49 sPLA2, induces LD formation in VSMCs. This biological effect is contingent upon the activity of key enzymes such as diacylglycerol O-acyltransferase (DGAT) and acyl-CoA: cholesterol acyltransferase (ACAT), as well as a contribution by peroxisome proliferator-activated receptors (PPARs), specifically the γ and β/δ subtypes.

Increasing CE hydrolysis in LDs

Neutral cholesteryl ester hydrolase (NCEH) hydrolyzes excess CEs to FC in LDs (Mulas et al., 2014; Yin et al., 2014; Dubland and Francis, 2015). This is the first step to start the reverse cholesterol transport (RCT). The FC from this process can be processed by two paths: one is re-esterification by ACAT1 in ER, and the other is efflux by ABC transporters (Sekiya et al., 2009; Escary et al., 1999). However, research related to the regulation of NCEH is limited in VSMCs. Additional research is necessary to determine the precise roles that NCEH plays in the level of FC as well as the process of cholesterol removal in VSMCs.

Cholesterol efflux through ABCG1 and ABCA1

During conditions of excessive lipid burden, ABCG1 and ABCA1 as transporters, along with SR-B, are responsible for a significant portion of cholesterol removal, accounting for approximately 60%-70% of the total efflux capacity (Jin et al., 2015) (Pownall et al., 2021). The cholesterol transporters ABCA1 and ABCG1 are recognized for their protective role against atherosclerosis (Phillips, 2014; Favari et al., 2015). ABCG1 is a mediator in the delivery of unbound cholesterol molecules to HDL particles, thereby participating in cholesterol transport mechanisms (Ouimet et al., 2019). An elevated expression of ABCG1 results in the increased transfer of unbound HDL particles, indicating its significant role in cholesterol efflux (Frambach et al., 2020). Nevertheless, mutation of ABCA1 in ApoE^{-/-} mice demonstrates minimal impact on the development of atherosclerotic plaques, suggesting a complex interplay of these factors in AS (Aiello et al., 2003). ABCA1 is vital because it promotes unesterified cholesterol transfer to ApoA-1 molecules that are deficient in lipids, thereby initiating the formation of HDL particles (Yvan-Charvet et al., 2007). Accumulated studies found that expression of ABCA1 was impaired in foam cells from VSMCs compared to foam cells that are derived from leukocytes (Wang Y. et al., 2019; Robichaud et al., 2022). The diminished capacity to expel surplus cholesterol is a principal factor driving VSMCs to become the primary source of foam cells in lesions (Lin et al., 2024).

It is known that KLF4 influences the phenotypic transition of intimal SMCs within atherosclerotic lesions (Kim et al., 2023). However, there has always been controversy regarding the relationship between KLF4 and ABCA1. Shankman and others suggested that the relationship between KLF4 and ABCA1 might be indirect or mediated by other factors (Shankman et al., 2015). In contrast, Bethany J Bogan et al. found that ABCA1 expression was a target of KLF4 (Bogan et al., 2024). Dubland et al. reported that oxysterol 27-hydroxycholesterol (27-OHC) is translocated into the nucleus, where it interacts with liver X receptors (LXRs) situated on the regulatory regions of the ABCA1 and ABCG1 genes. This binding event triggers an increase in the expression of these transporters, which, in turn, enhances the cellular mechanism to remove surplus free cholesterol (Dubland et al., 2021). Nuclear factor of activated T-cells 5 (NFAT5), which functions independently of calcineurin, is a key component of the NFAT family that induced lipid metabolism-related (Sod1, Plin2) and cholesterol efflux gene expression (ABCA1) (Kappert et al., 2021). Mao X et al. found substrate stiffness regulates cholesterol efflux through ABCA1 in VSMC-derived foam cells (Mao et al., 2021). Ganoderma lucidum spore powder (GLSP) has been shown to mitigate the progression of atherosclerosis and the associated calcification of the aorta by enhancing the cholesterol transport processes mediated by ABCA1/G1, which are crucial for maintaining cellular lipid balance (Zheng G. et al., 2023).

Molecular mechanisms of cholesterol uptake, homeostasis, and efflux in VSMCderived foam cells

Peroxisome proliferator-activated receptor gamma (PPAR γ)

As a vital transcription factor, PPARy regulates several genes involved in metabolizing lipids, glucose, and inflammation (Kamon et al., 2003; Tavares et al., 2007). As opposed to control wild-type (WT) mice, PPARy/ApoE double knockout mice obtained more severe lesions associated with atherosclerosis, indicating PPAR γ 's role in AS (Gao et al., 2020). Recent studies found that PPARy inhibited inflammatory cytokines induced by LPS and ACAT1 expression via the TLR4/MyD88/NF-kB signaling pathway, which inhibited the VSMC-derived foam cell formation (Yin et al., 2014; Zhang et al., 2011). In addition, PARP1 facilitates the translocation of PLIN2 and PLIN3 and disrupts the interaction between ABCG1 and PLIN1, which leads to the accumulation of LDs (Lin et al., 2024). Myotoxin III regulates the relocation of lipid droplet metabolism-related proteins, including PLIN2 and PLIN3, and SR-A and LOX-1 expression through PPAR-y in VSMCs (Giannotti et al., 2019). When VSMCs were changed into adipocytes, the expression of CCAAT enhancer-binding proteins (C/EBPa) and PPARy increased (Davies et al., 2005; Porse et al., 2001). A recent study suggests C/EBPa acetylation induces PPARy transactivation in macrophage-derived foam cells, suggesting that C/EBP α /PPAR γ may participate in VSMC-derived foam cells, but this needs to be further confirmed (Gao et al., 2020).

TLR4

In cultured SMCs, TLR4 regulates the expression of inflammation induced by ox-LDL. Yin et al. discovered that activation of TLR4/MyD88/NF-KB by ox-LDL increased ACAT1 expression and promoted VSMC foam cell formation (Yin et al., 2014). Once TLR4 is knocked out, atherosclerotic plaque and foam cells derived from VSMCs induced by high lipids are inhibited. Xiao He et al. further found that MgCl₂ inhibited the activation of the TLR4/NF-KB signaling pathway induced by ox-LDL, which attenuated pyroptosis of VSMCderived foam cells (He et al., 2023). Following further study, Zhiyang Han et al. pointed out that HOXA1 may contribute to the positive feedback relationship between TLR4 and NF-KB (Han et al., 2023). Recently, Chen Z et al. showed that TLR4 regulated ox-LDL-induced VSMC foam cell production via the Sirt1/3 and Src pathways (Chen et al., 2021; Yang et al., 2015). TLR4 also participates in the regulation of ROS recruitment in VSMCderived foam cells (Moldogazieva et al., 2019). Zhen Sun et al. suggested that macrophage CD36 can help TLR4 bind to foam cells (Sun et al., 2022). The above results suggest that TLR4 is involved in VSMC foam cell formation with ox-LDL inducement, which may be targeted in future research to develop effective therapeutic medications for AS.

P2RY12

A P2 receptor family member, P2RY12 includes P2RX/P2X ion channels and P2RY/P2Y G protein-coupled receptors (Walker et al., 2020). Recent studies showed levels of P2RY12 receptors in VSMCs were elevated during AS, as most VSMCs that are P2RY12-positive are situated proximate to foam cells and the plaque area (Pi et al., 2021). Conversely, in advanced AS, P2RY12 receptor activation mitigated the efflux of cholesterol as well as autophagy inhibition, which was through PI3K-AKT-mTOR *in vivo* and *in vitro* (Pi et al., 2021; Bao et al., 2024). Recent studies found that Gualou-Xiebai (GLXB), Geniposide, and Huanglian Jiedu, herbs used in Traditional Chinese medicine to treat AS, raised the levels of lipophagy via the P2RY12/PI3K/AKT signaling pathway (Lin et al., 2024; Pi et al., 2021; Bao et al., 2024).

mTOR signaling

Accumulated studies revealed the mechanistic target of rapamycin (mTOR), a downstream effector of PPARγ and P2RY12, participates in nutrient sensing and regulates autophagy in VSMC-derived foam cell formation (Kim et al., 2023; Pi et al., 2021; Zuo et al., 2023). Pi et al. suggested that the P2RY12 receptor inhibited autophagosomes through PI3K-AKT-mTOR in VSMCs, which were inhibited by inhibition of Cx43 (Pi et al., 2021; Qin et al., 2022). Kim et al. found PPARγ/mTORC2/FOXO3a-autophagy mitigated VSMC senescence (Kim et al., 2023). Wingless/Int-1 signaling further downregulates mTORC1/ribosomal protein S6 kinase 1 (p-P70S6) and limits VSMC cholesterol buildup in humans and atherosclerosis progression in mice (Awan et al., 2022). Bisdemethoxycurcumin (BDMC), possessing anti-oxidation, anti-inflammation, and other multi-pharmacological functions,

promotes autophagy and mitigates lipid droplets via the PDK1/ AKT/mTOR signaling pathway, which alleviates the accumulation of lipids in VSMCs. Therefore, it can be utilized in atherosclerosis treatment and avoidance as a therapeutic agent (Zuo et al., 2023).

TFEB

TFEB is a core transcription factor and regulates lysosome biogenesis and autophagy (Settembre et al., 2011). In VSMCs, activation of TFEB can modulate the migration and propagation of VSMCs, as well as reduce the formation of VSMC-derived foam cells (Pi et al., 2019; Wang YT. et al., 2019). Chen et al. found the sulfhydration of TFEB Cys212 increased nuclear translocation; LAPTM5 (biogenesis of lysosomes), LDLRAP1 (an autosomal recessive hypercholesterolemic gene known as LDL receptor cytoplasm tail binding protein), and Atg9A (associated with autophagosome formation) are its target genes (Chen Z. et al., 2022). TFEB also participates in the regulation of lysosomal acidification in macrophages. Recovery of lysosomal acidification is another challenge that VSMCs must face in lipid metabolism processes. Therefore, recovery of lysosomal acidification will be a strategy to rescue macrophage lysosomal dysfunction, and this strategy's applicability to VSMC-derived foam cells remains to be investigated.

Epsins

Epsin1 and Epsin2 are members of the ubiquitin-binding endocytic adapter protein family. In macrophages, epsins are responsible for regulating EC reprograming to mesenchymal lipid uptake and cholesterol efflux in macrophages coming from AS plaque (Dong et al., 2023; Dong et al., 2020; Cui et al., 2023). Epsins are a positive regulatory factor in atherosclerotic lesion formation. Epsins promote the development of atherosclerosis by preventing the ubiquitination and degradation of LRP-1 in macrophages and regulating calcium release from the ER by promoting the proteasomal degradation of IP3R1 through its ubiquitin interaction motif (UIM) in endothelial cells (Dong et al., 2020; Brophy et al., 2019). Recent studies found that lack of Epsins induced VSMC transfer into myofibroblasts and ECs, which benefits the repair of vascular injury. This process was regulated through OCT4 and KLF4 (Wang et al., 2024). Nevertheless, whether epsins are involved in the disruption of lipid metabolism in VSMCs and VSMC-derived foam cell transformation and, if so, their regulatory mechanisms, has not been explored.

Others

As a serine protease and a PCSK family member, proprotein convertase subtilisin/PCSK9 has an involvement in cardiovascular disease and dyslipidemia progression caused by atherosclerosis (Ragusa et al., 2021; Katsuki et al., 2022). A recent study revealed PCSK9 increased the lesions in mice fed with high-fat content and foam cell production in ox-LDL-treated VSMCs through lncRNA small nucleolar RNA host gene 16 (SNHG16)/histone-lysine N-methyltransferase enzyme (EZH2)/tumor necrosis factor receptor-associated factor 5 (TRAF5) (Liu et al., 2023). Homocysteine induces DNA hypermethylation in the promoter region of C1q/TNF-related protein 9 (CTRP9) via upregulated expression of DNA methyltransferase 1 (DNMT1) while also




FIGURE 3

Pathway of the formation of VSMC-derived foam cells induced by ox-LDL. Low-density lipoprotein receptor-related protein (LRP) plays a dual role in the process of transforming smooth muscle cells into foam cells induced by ox-LDL, including inducing lipid droplet formation and inhibiting the expression of the ATP-binding cassette transporter (ABC) ABCA1 through ERK1/2/p-cPLA2. LRP1 plays a dual role in the process where high-fat stimulation transforms smooth muscle cells into foam cells. Ox-LDL induces WNT5A autocrine and then activates WNT5A/DVL2/JNK signaling, which enhances the expression of CD36. TREM2 upregulates the expression of the scavenger receptor CD36 in VSMCs by inducing the phosphorylation of p38 mitogen-activated protein kinase and PPARy and increasing PPARy nuclear transcriptional activity. Ox-LDL induces the direct phosphorylation of Lyn and AKT through CD36 and then downregulates the expression of LDL via TFEB. Ox-LDL induces VSMC transformation to foam cells through the mtROS/c-Fos/LOX-1 signaling pathway, which promotes ox-LDL uptake. LKB1 inhibits VSMC-derived foam cell formation and atherosclerosis via phosphorylation of SIRT6 and subsequent inhibition of LOX-1 expression. ERK1/2, extracellular signal-regulated kinases 1 and 2; cPLA2, cytosolic phospholipase A2; WNT5A, Wingless-Type mouse marmary tumor virus (MMTV) integration site family member 5A; DVL2, Disheveled segment polarity protein 2; JNK, c-Jun N-terminal kinase; TREM2, triggering receptor expressed in myeloid cells 2; PPARy, peroxisome proliferator-activated-receptor gamma; AKT, protein kinase B; TFEB, transcription factor EB; LOX-1, Lectin-like oxidized low-density lipoprotein 1.

adversely regulating the deposition of lipids in VSMCs as mediated by ERs (Wang et al., 2023). Methyl-CpG binding protein 2 (MECP2)/ transcription factor homeobox A9 (HOXA9)/ E3 ubiquitin ligase Peli1 participated in VSMC phenotypic switching induced by ox-LDL (Fu et al., 2023; Burger et al., 2022). A protein that binds to β -galactoside, galectin-1 (Gal-1) serves as an abdominal aortic aneurysm (AAA) and atherosclerosis therapeutic target. It enables more foam cells to be formed and increase mitochondrial dysfunction in VSMCs; such effects can be avoided via recombinant Gal-1 treatment (Roldán-Montero et al., 2022) (Figure 3).

Conclusion

VSMCs are vital in atherosclerosis onset, progression, and all other stages. To date, it is known that VSMCs filled with lipids undertake expansion of clones and intima migration, from which lipid intake and foam cell phenotype acquisition occur and eventually become a part of the 30%–70% foam cells in atherosclerotic plaques in humans and mice. The origin of VSMC-derived foam cell formation is unclear. First, do VSMCs have predetermined mechanisms to regulate VSMC-derived

foam cell migration to the intima from the medial layer? Second, what is the relationship between VSMC-derived foam cells and specific clones of VSMCs in the intima? Finally, do VSMC-derived foam cells continue to proliferate?

VSMCs have developed sophisticated mechanisms for cholesterol metabolism. The procession of VSMCs switching to foam cells is associated with disturbances of cholesterol metabolism-regulating CE and free cholesterol levels. First, ox-LDL induced upregulation of LOX-1 and CD36 and induced ox-LDL internalization. The levels of phagocytosis capacity and SR (CD36, LOX1) expression can undergo gene-level influence. They can be significant interindividual susceptibility prognosticators in atherosclerosis and the formation of foam cells derived from VSMCs. Second, the imbalance of cholesterol esterification and free cholesterol was due to the upregulation of ACAT1 and downregulation of NCEH. Resounding proof exists that cholesterol trafficking is vital in intraarterial-cell cholesterol accumulation in both early- and late-stage atherosclerosis. Lysosomes and vesicular movements emerged as central components in cholesterol trafficking. Such mechanisms in cellular biology and physiology in cholesterol sensing and lysosomal function are important targets in atherosclerosis treatment and avoidance. Foam cells originating from VSMCs have defective

autophagy and expression of ABCA1 compared to macrophages in response to lipid loading, which contributes to cholesterol efflux impairment and dysfunctional lysosome accumulation. An in-depth study of the discrepancy between VSMC-derived foam cells and macrophage-derived foam cells will identify important targets for the treatment of atherosclerosis.

Author contributions

JG: conceptualization, funding acquisition, visualization, writing-original draft, and writing-review and editing. LD: conceptualization, funding acquisition, visualization, and writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study

References

Ackers, I., Szymanski, C., Silver, M. J., and Malgor, R. (2020). Oxidized low-density lipoprotein induces WNT5A signaling activation in THP-1 derived macrophages and a human aortic vascular smooth muscle cell line. *Front. Cardiovasc. Med.* 7, 567837. doi:10.3389/fcvm.2020.567837

Aiello, R. J., Brees, D., and Francone, O. L. (2003). ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. *Arteriosclerosis, thrombosis, Vasc. Biol.* 23 (6), 972–980. doi:10.1161/01.ATV. 0000054661.21499.FB

Alencar, G. F., Owsiany, K. M., Karnewar, S., Sukhavasi, K., Mocci, G., Nguyen, A. T., et al. (2020). Stem cell pluripotency genes Klf4 and Oct4 regulate complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis. *Circulation* 142 (21), 2045–2059. doi:10.1161/CIRCULATIONAHA.120.046672

Allahverdian, S., Chehroudi, A. C., McManus, B. M., Abraham, T., and Francis, G. A. (2014). Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. *Circulation* 129 (15), 1551–1559. doi:10.1161/CIRCULATIONAHA.113.005015

Andreeva, E. R., Pugach, I. M., and Orekhov, A. N. (1997). Subendothelial smooth muscle cells of human aorta express macrophage antigen *in situ* and *in vitro*. *Atherosclerosis* 135 (1), 19–27. doi:10.1016/s0021-9150(97)00136-6

Awan, S., Lambert, M., Imtiaz, A., Alpy, F., Tomasetto, C., Oulad-Abdelghani, M., et al. (2022). Wnt5a promotes lysosomal cholesterol egress and protects against atherosclerosis. *Circulation Res.* 130 (2), 184–199. doi:10.1161/circresaha.121.318881

Bai, J., Zhu, Y., He, L., Zhang, J., Li, J., Pan, R., et al. (2022). Saponins from bitter melon reduce lipid accumulation via induction of autophagy in *C. elegans* and HepG2 cell line. *Curr. Res. food Sci.* 5, 1167–1175. doi:10.1016/j.crfs.2022.06.011

Bao, Y., Zhu, L., Wang, Y., Liu, J., Liu, Z., Li, Z., et al. (2024). Gualou-Xiebai herb pair and its active ingredients act against atherosclerosis by suppressing VSMC-derived foam cell formation via regulating P2RY12-mediated lipophagy. *Phytomedicine Int. J. phytotherapy Phytopharm.* 128, 155341. doi:10.1016/j.phymed.2024.155341

Barquera, S., Pedroza-Tobías, A., Medina, C., Hernández-Barrera, L., Bibbins-Domingo, K., Lozano, R., et al. (2015). Global Overview of the epidemiology of atherosclerotic cardiovascular disease. *Archives Med. Res.* 46 (5), 328–338. doi:10. 1016/j.arcmed.2015.06.006

Bashore, A. C., Yan, H., Xue, C., Zhu, L. Y., Kim, E., Mawson, T., et al. (2024). Highdimensional single-cell multimodal landscape of human carotid atherosclerosis. *Arteriosclerosis, thrombosis, Vasc. Biol.* 44 (4), 930–945. doi:10.1161/ATVBAHA.123.320524

Becker, L., Gharib, S. A., Irwin, A. D., Wijsman, E., Vaisar, T., Oram, J. F., et al. (2010). A macrophage sterol-responsive network linked to atherogenesis. *Cell metab.* 11 (2), 125–135. doi:10.1016/j.cmet.2010.01.003

Ben, J., Zhu, X., Zhang, H., and Chen, Q. (2015). Class A1 scavenger receptors in cardiovascular diseases. Br. J. Pharmacol. 172 (23), 5523–5530. doi:10.1111/bph.13105

Bennett, M. R., Sinha, S., and Owens, G. K. (2016). Vascular smooth muscle cells in atherosclerosis. *Circulation Res.* 118 (4), 692–702. doi:10.1161/CIRCRESAHA.115. 306361

was funded by the High-Level Scientific and Technological Innovation Talent Cultivation Project of Henan University of Science and Technology First Affiliated Hospital.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Bogan, B. J., Williams, H. C., Holden, C. M., Patel, V., Joseph, G., Fierro, C., et al. (2024). The role of fatty acid synthase in the vascular smooth muscle cell to foam cell transition. *Cells* 13 (8), 658. doi:10.3390/cells13080658

Boucher, P., Gotthardt, M., Li, W. P., Anderson, R. G. W., and Herz, J. (2003). LRP: role in vascular wall integrity and protection from atherosclerosis. *Sci. (New York, N.Y.)* 300 (5617), 329–332. doi:10.1126/science.1082095

Boucher, P., Li, W. P., Matz, R. L., Takayama, Y., Auwerx, J., Anderson, R. G. W., et al. (2007). LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome. *PloS one* 2 (5), e448. doi:10. 1371/journal.pone.0000448

Brophy, M. L., Dong, Y., Tao, H., Yancey, P. G., Song, K., Zhang, K., et al. (2019). Myeloid-specific deletion of epsins 1 and 2 reduces atherosclerosis by preventing LRP-1 downregulation. *Circulation Res.* 124 (4), e6–e19. doi:10.1161/CIRCRESAHA.118. 313028

Burger, F., Baptista, D., Roth, A., Brandt, K. J., and Miteva, K. (2022). The E3 ubiquitin ligase Peli1 deficiency promotes atherosclerosis progression. *Cells* 11 (13), 2014. doi:10. 3390/cells11132014

Chappell, J., Harman, J. L., Narasimhan, V. M., Yu, H., Foote, K., Simons, B. D., et al. (2016). Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. *Circulation Res.* 119 (12), 1313–1323. doi:10.1161/CIRCRESAHA.116.309799

Chen, L., Zhao, Z. W., Zeng, P. H., Zhou, Y. J., and Yin, W. J. (2022a). Molecular mechanisms for ABCA1-mediated cholesterol efflux. *Cell cycle Georget. Tex.* 21 (11), 1121–1139. doi:10.1080/15384101.2022.2042777

Chen, Z., Ouyang, C., Zhang, H., Gu, Y., Deng, Y., Du, C., et al. (2022b). Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy. *Autophagy* 18 (10), 2270–2287. doi:10.1080/15548627.2022.026097

Chen, Z., Xue, Q., Cao, L., Wang, Y., Chen, Y., Zhang, X., et al. (2021). Toll-like receptor 4 mediated oxidized low-density lipoprotein-induced foam cell formation in vascular smooth muscle cells via Src and sirt1/3 pathway. *Mediat. Inflamm.* 2021, 6639252. doi:10.1155/2021/6639252

Clarke, M. C., Figg, N., Maguire, J. J., Davenport, A. P., Goddard, M., Littlewood, T. D., et al. (2006). Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. *Nat. Med.* 12 (9), 1075–1080. doi:10.1038/nm1459

Cochain, C., Vafadarnejad, E., Arampatzi, P., Pelisek, J., Winkels, H., Ley, K., et al. (2018). Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. *Circulation Res.* 122 (12), 1661–1674. doi:10.1161/CIRCRESAHA.117.312509

Conklin, A. C., Nishi, H., Schlamp, F., Örd, T., Õunap, K., Kaikkonen, M. U., et al. (2021). Meta-analysis of smooth muscle lineage transcriptomes in atherosclerosis and their relationships to *in vitro* models. *Immunometabolism* 3 (3), e210022. doi:10.20900/ immunometab20210022 Costales, P., Fuentes-Prior, P., Castellano, J., Revuelta-Lopez, E., Corral-Rodríguez, M. Á., Nasarre, L., et al. (2015). K domain CR9 of low density lipoprotein (LDL) receptor-related protein 1 (LRP1) is critical for aggregated LDL-induced foam cell formation from human vascular smooth muscle cells. *J. Biol. Chem.* 290 (24), 14852–14865. doi:10.1074/jbc.M115.638361

Cui, K., Gao, X., Wang, B., Wu, H., Arulsamy, K., Dong, Y., et al. (2023). Epsin nanotherapy regulates cholesterol transport to fortify atheroma regression. *Circulation Res.* 132 (1), e22–e42. doi:10.1161/CIRCRESAHA.122.321723

Daugherty, A., Cornicelli, J. A., Welch, K., Sendobry, S. M., and Rateri, D. L. (1997). Scavenger receptors are present on rabbit aortic endothelial cells *in vivo*. *Arteriosclerosis, thrombosis, Vasc. Biol.* 17 (11), 2369–2375. doi:10.1161/01.atv.17. 11.2369

Davies, J. D., Carpenter, K. L., Challis, I. R., Figg, N. L., McNair, R., Proudfoot, D., et al. (2005). Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. *J. Biol. Chem.* 280 (5), 3911–3919. doi:10.1074/jbc.M410075200

Deaton, R. A., Gan, Q., and Owens, G. K. (2009). Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle. *Am. J. physiology. Heart circulatory physiology* 296 (4), H1027–H1037. doi:10.1152/ajpheart.01230.2008

DeBose-Boyd, R. A., Ou, J., Goldstein, J. L., and Brown, M. S. (2001). Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. *Proc. Natl. Acad. Sci. U. S. A.* 98 (4), 1477–1482. doi:10.1073/pnas.98.4.1477

Deng, Q., Li, H., Yue, X., Guo, C., Sun, Y., Ma, C., et al. (2023). Smooth muscle liver kinase B1 inhibits foam cell formation and atherosclerosis via direct phosphorylation and activation of SIRT6. *Cell death and Dis.* 14 (8), 542. doi:10.1038/s41419-023-06054-x

Depuydt, M. A. C., Prange, K. H. M., Slenders, L., Örd, T., Elbersen, D., Boltjes, A., et al. (2020). Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. *Circulation Res.* 127 (11), 1437–1455. doi:10.1161/CIRCRESAHA. 120.316770

Dong, Y., Lee, Y., Cui, K., He, M., Wang, B., Bhattacharjee, S., et al. (2020). Epsinmediated degradation of IP3R1 fuels atherosclerosis. *Nat. Commun.* 11 (1), 3984. doi:10. 1038/s41467-020-17848-4

Dong, Y., Wang, B., Du, M., Zhu, B., Cui, K., Li, K., et al. (2023). Targeting epsins to inhibit fibroblast growth factor signaling while potentiating transforming growth factor- β signaling constrains endothelial-to-mesenchymal transition in atherosclerosis. *Circulation* 147 (8), 669–685. doi:10.1161/CIRCULATIONAHA.122.063075

Dubland, J. A., Allahverdian, S., Besler, K. J., Ortega, C., Wang, Y., Pryma, C. S., et al. (2021). Low LAL (lysosomal acid lipase) expression by smooth muscle cells relative to macrophages as a mechanism for arterial foam cell formation. *Arteriosclerosis, thrombosis, Vasc. Biol.* 41 (6), e354–e368. doi:10.1161/ATVBAHA.120.316063

Dubland, J. A., and Francis, G. A. (2015). Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. *Front. cell Dev. Biol.* 3, 3. doi:10.3389/ fcell.2015.00003

Dubland, J. A., and Francis, G. A. (2016). So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation. *Curr. Opin. Lipidol.* 27 (2), 155–161. doi:10.1097/MOL.0000000000279

Escary, J. L., Choy, H. A., Reue, K., Wang, X. P., Castellani, L. W., Glass, C. K., et al. (1999). Paradoxical effect on atherosclerosis of hormone-sensitive lipase overexpression in macrophages. *J. lipid Res.* 40 (3), 397–404. doi:10.1016/s0022-2275(20)32443-3

Favari, E., Chroni, A., Tietge, U. J., Zanotti, I., Escolà-Gil, J. C., and Bernini, F. (2015). Cholesterol efflux and reverse cholesterol transport. *Handb. Exp. Pharmacol.* 224, 181–206. doi:10.1007/978-3-319-09665-0_4

Febbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., et al. (2000). Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. *J. Clin. investigation* 105 (8), 1049–1056. doi:10.1172/JCI9259

Feil, S., Fehrenbacher, B., Lukowski, R., Essmann, F., Schulze-Osthoff, K., Schaller, M., et al. (2014). Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. *Circulation Res.* 115 (7), 662–667. doi:10.1161/ CIRCRESAHA.115.304634

Frambach, S., de Haas, R., Smeitink, J. A. M., Rongen, G. A., Russel, F. G. M., and Schirris, T. J. J. (2020). Brothers in arms: ABCA1-and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment. *Pharmacol. Rev.* 72 (1), 152–190. doi:10.1124/pr.119.017897

Fu, X., Fu, P., Yang, T., and Niu, T. (2023). Homeobox A9 is a novel mediator of vascular smooth muscle cell phenotypic switching and proliferation by regulating methyl-CpG binding protein 2. *Cell. Signal.* 108, 110695. doi:10.1016/j.cellsig.2023. 110695

Gao, J., Ye, H., and Serrero, G. (2000). Stimulation of adipose differentiation related protein (ADRP) expression in adipocyte precursors by long-chain fatty acids. *J. Cell. physiology* 182 (2), 297–302. doi:10.1002/(SICI)1097-4652(200002)182:2<297::AID-JCP19>3.0.CO;2-Z

Gao, Q., Wei, A., Chen, F., Chen, X., Ding, W., Ding, Z., et al. (2020). Enhancing PPAR γ by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice. *Pharmacol. Res.* 160, 105059. doi:10.1016/j.phrs.2020.105059

Giannotti, K. C., Weinert, S., Viana, M. N., Leiguez, E., Araujo, T. L. S., Laurindo, F. R. M., et al. (2019). A secreted phospholipase A(2) induces Formation of smooth muscle foam cells which transdifferentiate to macrophage-like state. *Mol. Basel, Switz.* 24 (18), 3244. doi:10.3390/molecules24183244

Glerup, S., Schulz, R., Laufs, U., and Schlüter, K. D. (2017). Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. *Basic Res. Cardiol.* 112 (3), 32. doi:10.1007/s00395-017-0619-0

Gong, Q., and Pitas, R. E. (1995). Synergistic effects of growth factors on the regulation of smooth muscle cell scavenger receptor activity. *J. Biol. Chem.* 270 (37), 21672–21678. doi:10.1074/jbc.270.37.21672

Gordts, P. L., Reekmans, S., Lauwers, A., Van Dongen, A., Verbeek, L., and Roebroek, A. J. M. (2009). Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. *Arteriosclerosis, thrombosis, Vasc. Biol.* 29 (9), 1258–1264. doi:10.1161/ATVBAHA.109.192211

Graves, L. M., Bornfeldt, K. E., Sidhu, J. S., Argast, G. M., Raines, E. W., Ross, R., et al. (1996). Platelet-derived growth factor stimulates protein kinase A through a mitogenactivated protein kinase-dependent pathway in human arterial smooth muscle cells. *J. Biol. Chem.* 271 (1), 505–511. doi:10.1074/jbc.271.1.505

Grootaert, M. O. J., and Bennett, M. R. (2021). Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. *Cardiovasc. Res.* 117 (11), 2326–2339. doi:10. 1093/cvr/cvab046

Guo, X., Li, B., Wen, C., Zhang, F., Xiang, X., Nie, L., et al. (2023). TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis. *Cell. Mol. life Sci. CMLS* 80 (5), 137. doi:10.1007/s00018-023-04786-9

Han, Z., Hu, H., Yin, M., Lin, Y., Yan, Y., Han, P., et al. (2023). HOXA1 participates in VSMC-to-macrophage-like cell transformation via regulation of NF-kB p65 and KLF4: a potential mechanism of atherosclerosis pathogenesis. *Mol. Med. Camb. Mass.* 29 (1), 104. doi:10.1186/s10020-023-00685-8

He, X., Bai, Q., Zhang, X., and Zhang, L. (2023). MgCl(2) attenuates ox-LDL-induced vascular smooth muscle-derived foam cells pyroptosis by downregulating the TLR4/ NF-κB signaling pathway. *Biol. trace Elem. Res.* 201 (11), 5242–5256. doi:10.1007/s12011-023-03585-4

Higashimori, M., Tatro, J. B., Moore, K. J., Mendelsohn, M. E., Galper, J. B., and Beasley, D. (2011). Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. *Arteriosclerosis, thrombosis, Vasc. Biol.* 31 (1), 50–57. doi:10.1161/ATVBAHA.110.210971

Hofnagel, O., Luechtenborg, B., Plenz, G., and Robenek, H. (2002). Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. *Arteriosclerosis, thrombosis, Vasc. Biol.* 22 (4), 710–711. doi:10.1161/01.atv.0000012402.85056.45

Ho-Tin-Noé, B., Vo, S., Bayles, R., Ferrière, S., Ladjal, H., Toumi, S., et al. (2017). Cholesterol crystallization in human atherosclerosis is triggered in smooth muscle cells during the transition from fatty streak to fibroatheroma. *J. pathology* 241 (5), 671–682. doi:10.1002/path.4873

Huang, J., and Kontos, C. D. (2002). Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. *Arteriosclerosis, thrombosis, Vasc. Biol.* 22 (5), 745–751. doi:10.1161/01.atv. 0000016358.05294.8d

Jacobsen, K., Lund, M. B., Shim, J., Gunnersen, S., Füchtbauer, E. M., Kjolby, M., et al. (2017). Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs. *JCI insight* 2 (19), e95890. doi:10.1172/jci.insight. 95890

Jeong, S. J., Stitham, J., Evans, T. D., Zhang, X., Rodriguez-Velez, A., Yeh, Y. S., et al. (2021). Trehalose causes low-grade lysosomal stress to activate TFEB and the autophagy-lysosome biogenesis response. *Autophagy* 17 (11), 3740–3752. doi:10. 1080/15548627.2021.1896906

Jin, X., Freeman, S. R., Vaisman, B., Liu, Y., Chang, J., Varsano, N., et al. (2015). ABCA1 contributes to macrophage deposition of extracellular cholesterol. *J. lipid Res.* 56 (9), 1720–1726. doi:10.1194/jlr.M060053

Kamon, J., Yamauchi, T., Terauchi, Y., Kubota, N., and Kadowaki, T. (2003). The mechanisms by which PPARgamma and adiponectin regulate glucose and lipid metabolism. *Folia Pharmacol. Jpn.* 122 (4), 294–300. doi:10.1254/fpj.122.294

Kappert, L., Ruzicka, P., Kutikhin, A., De La Torre, C., Fischer, A., Hecker, M., et al. (2021) "Loss of Nfat5 promotes lipid accumulation in vascular smooth muscle cells. *FASEB J.* 35. doi:10.1096/fj.202100682R

Katsuki, S., P. K. J., Lupieri, A., Nakano, T., Passos, L. S. A., Rogers, M. A., et al. (2022). Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes macrophage activation via LDL receptor-independent mechanisms. *Circulation Res.* 131 (11), 873–889. doi:10. 1161/CIRCRESAHA.121.320056

Kim, S. G., Sung, J. Y., Kang, Y. J., and Choi, H. C. (2023). PPARγ activation by fisetin mitigates vascular smooth muscle cell senescence via the mTORC2-FoxO3a-autophagy signaling pathway. *Biochem. Pharmacol.* 218, 115892. doi:10.1016/j.bcp.2023.115892

Kodama, T., Freeman, M., Rohrer, L., Zabrecky, J., Matsudaira, P., and Krieger, M. (1990). Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. *Nature* 343 (6258), 531–535. doi:10.1038/343531a0

Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., et al. (2019). Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. *J. Clin. investigation* 129 (5), 2164. doi:10.1172/JCI129277

Kzhyshkowska, J., Neyen, C., and Gordon, S. (2012). Role of macrophage scavenger receptors in atherosclerosis. *Immunobiology* 217 (5), 492–502. doi:10.1016/j.imbio. 2012.02.015

Li, H., Freeman, M. W., and Libby, P. (1995). Regulation of smooth muscle cell scavenger receptor expression *in vivo* by atherogenic diets and *in vitro* by cytokines. *J. Clin. investigation* 95 (1), 122–133. doi:10.1172/JCI117628

Lin, J., Wang, X., Gu, M., Chen, Y., Xu, J., Chau, N. V., et al. (2024). Geniposide ameliorates atherosclerosis by restoring lipophagy via suppressing PARP1/PI3K/AKT signaling pathway. *Phytomedicine Int. J. phytotherapy Phytopharm.* 129, 155617. doi:10. 1016/j.phymed.2024.155617

Lin, L. L., Lin, A. Y., and Knopf, J. L. (1992). Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. *Proc. Natl. Acad. Sci. U. S. A.* 89 (13), 6147–6151. doi:10.1073/pnas.89.13.6147

Liu, Y., Zhao, Y., Feng, P., and Jiang, H. (2023). PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16/EZH2/TRAF5-mediated VSMC proliferation, migration, and foam cell formation. *Cell Biol. Int.* 47 (7), 1267–1280. doi:10.1002/cbin. 12018

Liu, Y. X., Yuan, P. Z., Wu, J. H., and Hu, B. (2021). Lipid accumulation and novel insight into vascular smooth muscle cells in atherosclerosis. *J. Mol. Med. Berlin, Ger.* 99 (11), 1511–1526. doi:10.1007/s00109-021-02109-8

Llorente-Cortés, V., and Badimon, L. (2005). LDL receptor-related protein and the vascular wall: implications for atherothrombosis. *Arteriosclerosis, thrombosis, Vasc. Biol.* 25 (3), 497–504. doi:10.1161/01.ATV.0000154280.62072.fd

Llorente-Cortés, V., Martínez-González, J., and Badimon, L. (2000). LDL receptorrelated protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. *Arteriosclerosis, thrombosis, Vasc. Biol.* 20 (6), 1572–1579. doi:10.1161/01.atv.20.6. 1572

Llorente-Cortés, V., Otero-Viñas, M., Sánchez, S., Rodríguez, C., and Badimon, L. (2002). Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. *Circulation* 106 (24), 3104–3110. doi:10.1161/01.cir.0000041434.28573.0b

Ma, C., Xia, R., Yang, S., Liu, L., Zhang, J., Feng, K., et al. (2020). Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE(-/-) mice. *Theranostics* 10 (3), 1090–1106. doi:10.7150/thno.38115

Ma, S., Yang, D., Li, D., Tang, B., and Yang, Y. (2011). Oleic acid induces smooth muscle foam cell formation and enhances atherosclerotic lesion development via CD36. *Lipids health Dis.* 10, 53. doi:10.1186/1476-511X-10-53

Manning-Tobin, J. J., Moore, K. J., Seimon, T. A., Bell, S. A., Sharuk, M., Alvarez-Leite, J. I., et al. (2009). Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. *Arteriosclerosis, thrombosis, Vasc. Biol.* 29 (1), 19–26. doi:10.1161/ATVBAHA.108. 176644

Mao, X., Tan, Y., Wang, H., Li, S., and Zhou, Y. (2021). Substrate stiffness regulates cholesterol efflux in smooth muscle cells. *Front. cell Dev. Biol.* 9, 648715. doi:10.3389/ fcell.2021.648715

Mehta, J. L., Sanada, N., Hu, C. P., Chen, J., Dandapat, A., Sugawara, F., et al. (2007). Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. *Circulation Res.* 100 (11), 1634–1642. doi:10.1161/CIRCRESAHA.107.149724

Miao, G., Zhao, X., Chan, S. L., Zhang, L., Li, Y., Zhang, Y., et al. (2022). Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis. *Metabolism Clin. Exp.* 132, 155213. doi:10.1016/j.metabol.2022.155213

Minami, M., Kume, N., Shimaoka, T., Kataoka, H., Hayashida, K., Akiyama, Y., et al. (2001). Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. *Arteriosclerosis, thrombosis, Vasc. Biol.* 21 (11), 1796–1800. doi:10.1161/hq1001. 096652

Mineo, C., and Shaul, P. W. (2003). HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. *Trends Cardiovasc. Med.* 13 (6), 226–231. doi:10.1016/s1050-1738(03)00098-7

Misra, A., Feng, Z., Chandran, R. R., Kabir, I., Rotllan, N., Aryal, B., et al. (2018). Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. *Nat. Commun.* 9 (1), 2073. doi:10.1038/s41467-018-04447-7

Moldogazieva, N. T., Mokhosoev, I. M., Mel'nikova, T. I., Porozov, Y. B., and Terentiev, A. A. (2019). Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age-related diseases. *Oxidative Med. Cell. Longev.* 2019, 3085756. doi:10.1155/2019/3085756

Moore, K. J., and Freeman, M. W. (2006). Scavenger receptors in atherosclerosis: beyond lipid uptake. *Arteriosclerosis, thrombosis, Vasc. Biol.* 26 (8), 1702–1711. doi:10. 1161/01.ATV.0000229218.97976.43

Mulas, M. F., Maxia, A., Dessì, S., and Mandas, A. (2014). Cholesterol esterification as a mediator of proliferation of vascular smooth muscle cells and peripheral blood mononuclear cells during atherogenesis. *J. Vasc. Res.* 51 (1), 14–26. doi:10.1159/000355218

Oladosu, O., Esobi, I. C., Powell, R. R., Bruce, T., and Stamatikos, A. (2023). Dissecting the impact of vascular smooth muscle cell ABCA1 versus ABCG1 expression on cholesterol efflux and macrophage-like cell transdifferentiation: the role of SR-BI. *J. Cardiovasc. Dev. Dis.* 10 (10), 416. doi:10.3390/jcdd10100416

Oquendo, P., Hundt, E., Lawler, J., and Seed, B. (1989). CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. *Cell* 58 (1), 95–101. doi:10.1016/0092-8674(89)90406-6

Ouimet, M., Barrett, T. J., and Fisher, E. A. (2019). HDL and reverse cholesterol transport. *Circulation Res.* 124 (10), 1505–1518. doi:10.1161/CIRCRESAHA.119. 312617

Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., and Marcel, Y. L. (2011). Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. *Cell metab.* 13 (6), 655–667. doi:10.1016/j.cmet.2011.03.023

Pan, H., Xue, C., Auerbach, B. J., Fan, J., Bashore, A. C., Cui, J., et al. (2020). Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. *Circulation* 142 (21), 2060–2075. doi:10.1161/CIRCULATIONAHA.120.048378

Pan, X., Liu, J., Zhong, L., Zhang, Y., Liu, C., Gao, J., et al. (2023). Identification of lipid metabolism-related biomarkers for diagnosis and molecular classification of atherosclerosis. *Lipids health Dis.* 22 (1), 96. doi:10.1186/s12944-023-01864-6

Park, Y. M. (2014). CD36, a scavenger receptor implicated in atherosclerosis. *Exp. and Mol. Med.* 46 (6), e99. doi:10.1038/emm.2014.38

Paul, A., Chang, B. H., Li, L., and Yechoor, V. K. (2008). Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. *Circulation Res.* 102 (12), 1492–1501. doi:10.1161/CIRCRESAHA. 107.168070

Phillips, M. C. (2014). Molecular mechanisms of cellular cholesterol efflux. J. Biol. Chem. 289 (35), 24020-24029. doi:10.1074/jbc.R114.583658

Pi, H., Wang, Z., Liu, M., Deng, P., Yu, Z., Zhou, Z., et al. (2019). SCD1 activation impedes foam cell formation by inducing lipophagy in oxLDL-treated human vascular smooth muscle cells. *J. Cell. Mol. Med.* 23 (8), 5259–5269. doi:10.1111/jcmm.14401

Pi, S., Mao, L., Chen, J., Shi, H., Liu, Y., Guo, X., et al. (2021). The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. *Autophagy* 17 (4), 980–1000. doi:10.1080/15548627.2020.1741202

Porse, B. T., Pedersen, T. A., Xu, X., Lindberg, B., Wewer, U. M., Friis-Hansen, L., et al. (2001). E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis *in vivo. Cell* 107 (2), 247–258. doi:10.1016/s0092-8674(01)00516-5

Pownall, H. J., Rosales, C., Gillard, B. K., and Gotto, A. M., Jr (2021). High-density lipoproteins, reverse cholesterol transport and atherogenesis. *Nat. Rev. Cardiol.* 18 (10), 712–723. doi:10.1038/s41569-021-00538-z

PrabhuDas, M. R., Baldwin, C. L., Bollyky, P. L., Bowdish, D. M. E., Drickamer, K., Febbraio, M., et al. (2017). A consensus definitive classification of scavenger receptors and their roles in health and disease. *J. Immunol. Baltim. Md* 198 (10), 3775–3789. doi:10.4049/jimmunol.1700373

Qin, X., He, W., Yang, R., Liu, L., Zhang, Y., Li, L., et al. (2022). Inhibition of Connexin 43 reverses ox-LDL-mediated inhibition of autophagy in VSMC by inhibiting the PI3K/ Akt/mTOR signaling pathway. *PeerJ* 10, e12969. doi:10.7717/peerj.12969

Ragusa, R., Basta, G., Neglia, D., De Caterina, R., Del Turco, S., and Caselli, C. (2021). PCSK9 and atherosclerosis: looking beyond LDL regulation. *Eur. J. Clin. investigation* 51 (4), e13459. doi:10.1111/eci.13459

Rao, X., Zhong, J., Maiseyeu, A., Gopalakrishnan, B., Villamena, F. A., Chen, L. C., et al. (2014). CD36-dependent 7-ketocholesterol accumulation in macrophages mediates progression of atherosclerosis in response to chronic air pollution exposure. *Circulation Res.* 115 (9), 770–780. doi:10.1161/CIRCRESAHA.115.304666

Robichaud, S., Fairman, G., Vijithakumar, V., Mak, E., Cook, D. P., Pelletier, A. R., et al. (2021). Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells. *Autophagy* 17 (11), 3671–3689. doi:10. 1080/15548627.2021.1886839

Robichaud, S., Rasheed, A., Pietrangelo, A., Doyoung Kim, A., Boucher, D. M., Emerton, C., et al. (2022). Autophagy is differentially regulated in leukocyte and nonleukocyte foam cells during atherosclerosis. *Circulation Res.* 130 (6), 831–847. doi:10.1161/CIRCRESAHA.121.320047

Roldán-Montero, R., Pérez-Sáez, J. M., Cerro-Pardo, I., Oller, J., Martinez-Lopez, D., Nuñez, E., et al. (2022). Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm. *Sci. Adv.* 8 (11), eabm7322. doi:10. 1126/sciadv.abm7322

Rong, J. X., Shapiro, M., Trogan, E., and Fisher, E. A. (2003). Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. *Proc. Natl. Acad. Sci. U. S. A.* 100 (23), 13531–13536. doi:10.1073/pnas.1735526100

Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 362 (6423), 801-809. doi:10.1038/362801a0 Rudel, L. L., Lee, R. G., and Cockman, T. L. (2001). Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. *Curr. Opin. Lipidol.* 12 (2), 121–127. doi:10.1097/00041433-200104000-00005

Rykaczewska, U., Zhao, Q., Saliba-Gustafsson, P., Lengquist, M., Kronqvist, M., Bergman, O., et al. (2022). Plaque evaluation by ultrasound and transcriptomics reveals BCLAF1 as a regulator of smooth muscle cell lipid transdifferentiation in atherosclerosis. *Arteriosclerosis, thrombosis, Vasc. Biol.* 42 (5), 659–676. doi:10.1161/ATVBAHA.121.317018

Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., et al. (1997). An endothelial receptor for oxidized low-density lipoprotein. *Nature* 386 (6620), 73–77. doi:10.1038/386073a0

Schaeffer, D. F., Riazy, M., Parhar, K. S., Chen, J. H., Duronio, V., Sawamura, T., et al. (2009). LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma. *J. lipid Res.* 50 (8), 1676–1684. doi:10. 1194/jlr.M900167-JLR200

Schlich, R., Lamers, D., Eckel, J., and Sell, H. (2015). Adipokines enhance oleic acidinduced proliferation of vascular smooth muscle cells by inducing CD36 expression. *Archives physiology Biochem.* 121 (3), 81–87. doi:10.3109/13813455.2015.1045520

Sekiya, M., Osuga, J., Nagashima, S., Ohshiro, T., Igarashi, M., Okazaki, H., et al. (2009). Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis. *Cell metab.* 10 (3), 219–228. doi:10.1016/j.cmet.2009.08.004

Settembre, C., Di Malta, C., Polito, V. A., Garcia Arencibia, M., Vetrini, F., Erdin, S., et al. (2011). TFEB links autophagy to lysosomal biogenesis. *Sci. (New York, N.Y.)* 332 (6036), 1429–1433. doi:10.1126/science.1204592

Shankman, L. S., Gomez, D., Cherepanova, O. A., Salmon, M., Alencar, G. F., Haskins, R. M., et al. (2015). KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. *Nat. Med.* 21 (6), 628–637. doi:10. 1038/nm.3866

Shen, W. J., Azhar, S., and Kraemer, F. B. (2018). SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. *Annu. Rev. physiology* 80, 95–116. doi:10.1146/ annurev-physiol-021317-121550

Shu, H., Peng, Y., Hang, W., Nie, J., Zhou, N., and Wang, D. W. (2022). The role of CD36 in cardiovascular disease. *Cardiovasc. Res.* 118 (1), 115–129. doi:10.1093/cvr/ cvaa319

Suckling, K. E., and Stange, E. F. (1985). Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. *J. lipid Res.* 26 (6), 647–671. doi:10.1016/s0022-2275(20)34322-4

Sun, Z., Yuan, W., Li, L., Cai, H., Mao, X., Zhang, L., et al. (2022). Macrophage CD36 and TLR4 cooperation promotes foam cell formation and VSMC migration and proliferation under circadian oscillations. *J. Cardiovasc. Transl. Res.* 15 (5), 985–997. doi:10.1007/s12265-022-10225-0

Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., et al. (1997). A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature* 386 (6622), 292–296. doi:10.1038/386292a0

Tavares, V., Hirata, M. H., and Hirata, R. D. (2007). Peroxisome proliferator-activated receptor gamma (PPARgamma): molecular study in glucose homeostasis, lipid metabolism and therapeutic approach. *Arq. Bras. Endocrinol. Metabol.* 51 (4), 526–533. doi:10.1590/s0004-27302007000400005

Wågsäter, D., Olofsson, P. S., Norgren, L., Stenberg, B., and Sirsjö, A. (2004). The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. *Biochem. biophysical Res. Commun.* 325 (4), 1187–1193. doi:10.1016/j.bbrc.2004.10.160

Walker, D. G., Tang, T. M., Mendsaikhan, A., Tooyama, I., Serrano, G. E., Sue, L. I., et al. (2020). Patterns of expression of purinergic receptor P2RY12, a putative marker for non-activated microglia, in aged and alzheimer's disease brains. *Int. J. Mol. Sci.* 21 (2), 678. doi:10.3390/ijms21020678

Wang, B., Cui, K., Zhu, B., Dong, Y., Wang, D., Singh, B., et al. (2024). Epsins oversee smooth muscle cell reprograming by influencing master regulators KLF4 and OCT4. *bioRxiv Prepr. Serv. Biol.* doi:10.1101/2024.01.08.574714

Wang, Q., Wu, J., Zeng, Y., Chen, K., Wang, C., Yang, S., et al. (2020). Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease. *Clin. chimica acta; Int. J. Clin. Chem.* 510, 62–72. doi:10.1016/j.cca.2020.06.044

Wang, X., Ma, X., Zeng, Y., Xu, L., and Zhang, M. (2023). Hypermethylation of the CTRP9 promoter region promotes Hcy induced VSMC lipid deposition and foam cell formation via negatively regulating ER stress. *Sci. Rep.* 13 (1), 19438. doi:10.1038/ s41598-023-46981-5

Wang, Y., Dubland, J. A., Allahverdian, S., Asonye, E., Sahin, B., Jaw, J. E., et al. (2019a). Smooth muscle cells contribute the majority of foam cells in ApoE (apolipoprotein E)-Deficient mouse atherosclerosis. *Arteriosclerosis, thrombosis, Vasc. Biol.* 39 (5), 876–887. doi:10.1161/ATVBAHA.119.312434

Wang, Y. T., Chen, J., Li, X., Umetani, M., Chen, Y., Li, P. L., et al. (2019b). Contribution of transcription factor EB to adipoRon-induced inhibition of arterial smooth muscle cell proliferation and migration. *Am. J. physiology. Cell physiology* 317 (5), C1034-C1047-c1047. doi:10.1152/ajpcell.00294.2019

Willemsen, L., and de Winther, M. P. (2020). Macrophage subsets in atherosclerosis as defined by single-cell technologies. *J. pathology* 250 (5), 705–714. doi:10.1002/path. 5392

Xu, S., Ogura, S., Chen, J., Little, P. J., Moss, J., and Liu, P. (2013). LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. *Cell. Mol. life Sci. CMLS* 70 (16), 2859–2872. doi:10.1007/s00018-012-1194-z

Xue, J. H., Yuan, Z., Wu, Y., Liu, Y., Zhao, Y., Zhang, W. p., et al. (2010). High glucose promotes intracellular lipid accumulation in vascular smooth muscle cells by impairing cholesterol influx and efflux balance. *Cardiovasc. Res.* 86 (1), 141–150. doi:10.1093/cvr/ cvp388

Yan, P., Xia, C., Duan, C., Li, S., and Mei, Z. (2011). Biological characteristics of foam cell formation in smooth muscle cells derived from bone marrow stem cells. *Int. J. Biol. Sci.* 7 (7), 937–946. doi:10.7150/ijbs.7.937

Yang, K., Wang, X., Liu, Z., Lu, L., Mao, J., Meng, H., et al. (2015). Oxidized lowdensity lipoprotein promotes macrophage lipid accumulation via the toll-like receptor 4-Src pathway. *Circulation J. official J. Jpn. Circulation Soc.* 79 (11), 2509–2516. doi:10. 1253/circj.CJ-15-0345

Yin, Y. W., Liao, S. Q., Zhang, M. J., Liu, Y., Li, B. H., Zhou, Y., et al. (2014). TLR4mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. *Cell death and Dis.* 5 (12), e1574. doi:10.1038/cddis. 2014.535

Yin, Z., Zhang, J., Zhao, M., Liu, J., Xu, Y., Peng, S., et al. (2024). EDIL3/Del-1 prevents aortic dissection through enhancing internalization and degradation of apoptotic vascular smooth muscle cells. *Autophagy*, 1–21. doi:10.1080/15548627.2024.2367191

Yoo, J., Jeong, I. K., AhnFenofibrate, K.Ja PPARα agonist, and Hwang, Y. C. (2021). Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy. *Metabolism Clin. Exp.* 120, 154798. doi:10.1016/j.metabol.2021.154798

Yu, H., Fellows, A., Foote, K., Yang, Z., Figg, N., Littlewood, T., et al. (2018). FOXO3a (Forkhead transcription factor O subfamily member 3a) links vascular smooth muscle cell apoptosis, matrix breakdown, atherosclerosis, and vascular remodeling through a novel pathway involving MMP13 (matrix metalloproteinase 13). *Arteriosclerosis, thrombosis, Vasc. Biol.* 38 (3), 555–565. doi:10.1161/ATVBAHA.117.310502

Yu, X. H., Fu, Y. C., Zhang, D. W., Yin, K., and Tang, C. K. (2013). Foam cells in atherosclerosis. *Clin. chimica acta; Int. J. Clin. Chem.* 424, 245–252. doi:10.1016/j.cca. 2013.06.006

Yuan, Y., Li, P., and Ye, J. (2012). Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. *Protein and cell* 3 (3), 173–181. doi:10.1007/s13238-012-2025-6

Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L. D., Osborne-Lawrence, S., Lu, P., et al. (2001). High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. *Nat. Med.* 7 (7), 853–857. doi:10.1038/89986

Yurdagul, A., Jr., Subramanian, M., Wang, X., Crown, S. B., Ilkayeva, O. R., Darville, L., et al. (2020). Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. *Cell metab.* 31 (3), 518–533. doi:10. 1016/j.cmet.2020.01.001

Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., et al. (2007). Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. *J. Clin. investigation* 117 (12), 3900–3908. doi:10. 1172/JCI33372

Zanoni, P., Velagapudi, S., Yalcinkaya, M., Rohrer, L., and von Eckardstein, A. (2018). Endocytosis of lipoproteins. *Atherosclerosis* 275, 273–295. doi:10.1016/j.atherosclerosis. 2018.06.881

Zhang, L. L., Gao, C. Y., Fang, C. Q., Wang, Y. J., Gao, D., Yao, G. E., et al. (2011). PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells. *Cardiovasc. Res.* 92 (3), 484–493. doi:10.1093/cvr/cvr238

Zhang, W., Zhang, L., and Zhang, X. (2022). Anti-atherosclerotic effects of genistein in preventing ox-low-density lipoprotein-induced smooth muscle-derived foam cell formation via inhibiting SRC expression and L-Ca channel currents. *Ann. Transl. Med.* 10 (12), 700. doi:10.21037/atm-22-2113

Zhao, J., Niu, X., Yu, J., Xiao, X., Li, W., Zang, L., et al. (2020). Poria cocos polysaccharides attenuated ox-LDL-induced inflammation and oxidative stress via ERK activated Nrf2/HO-1 signaling pathway and inhibited foam cell formation in VSMCs. *Int. Immunopharmacol.* 80, 106173. doi:10.1016/j.intimp.2019.106173

Zheng, G., Zhao, Y., Li, Z., Hua, Y., Zhang, J., Miao, Y., et al. (2023b). GLSP and GLSP-derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis. *Theranostics* 13 (4), 1325–1341. doi:10.7150/thno.80250

Zheng, Y., Chen, B., Zhang, M., Ma, Y., Wang, L., Zhang, J., et al. (2023a). Autophagic degradation of LOX-1 is involved in the maintenance of vascular integrity injured by oxLDL and protected by Berberine. *Int. J. Biol. Sci.* 19 (6), 1813–1830. doi:10.7150/ijbs.80958

Zhou, Y., Zhou, H., Hua, L., Hou, C., Jia, Q., Chen, J., et al. (2021). Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis. *Free Radic. Biol. and Med.* 171, 55–68. doi:10.1016/j. freeradbiomed.2021.05.009

Zuo, J., Guo, S., and Qin, X. (2023). Bisdemethoxycurcumin suppresses the progression of atherosclerosis and VSMC-derived foam cell formation by promoting lipophagy. *Naunyn-Schmiedeberg's archives Pharmacol.* 396 (12), 3659–3670. doi:10.1007/s00210-023-02558-7